Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 16/20 | 0.52 |
| ▸ | CCNC | P24863 | 2/20 | 0.51 |
| ▸ | CDK8 | P49336 | 2/20 | 0.51 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.47 |
| ▸ | HSPB1 | P04792 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.47 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10138555 | 0.84 | CCNC (0.53) | MAPK14CCNCCDK8SLC22A12 | |
| SCHEMBL16432439 | 0.84 | CNR1 (0.47) | MAPK14DYRK1A | |
| SCHEMBL16211915 | 0.83 | CCNC (0.70) | MAPK14CCNCCDK8SLC22A12 | |
| SCHEMBL16212201 | 0.81 | CCNC (0.47) | CCNCCDK8SLC22A12 | |
| SCHEMBL16222216 | 0.81 | CCNC (0.50) | CCNCCDK8SLC22A12 | |
| SCHEMBL16211976 | 0.80 | SCN2A (0.64) | CCNCCDK8DYRK1ASLC22A12 | |
| SCHEMBL10138554 | 0.80 | CCNC (0.68) | CCNCCDK8CYP2C9SLC22A12 | |
| SCHEMBL18731320 | 0.80 | CCNC (0.48) | CCNCCDK8SLC22A12 | |
| SCHEMBL16211923 | 0.80 | CCNC (0.46) | CCNCCDK8SLC22A12 | |
| SCHEMBL18731268 | 0.80 | CCNC (0.48) | CCNCCDK8SLC22A12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2991635-B1 | NEUROGENESIS-STIMULATING ISOQUINOLINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2017-04-12 | — | — | EP | claimed |
| US-9586903-B2 | Isoquinoline derivatives | HOFFMANN-LA ROCHE INC. (US) | 2017-03-07 | — | — | US | claimed |
| EP-2991635-A1 | NEUROGENESIS-STIMULATING ISOQUINOLINE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2016-03-09 | — | — | EP | claimed |
| US-20160046583-A1 | ISOQUINOLINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2016-02-18 | — | — | US | claimed |
| WO-2014177596-A1 | NEUROGENESIS-STIMULATING ISOQUINOLINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2014-11-06 | — | — | WO | claimed |
| EP-2991635-B1 | NEUROGENESIS-STIMULATING ISOQUINOLINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2017-04-12 | — | — | EP | disclosed |
| EP-2991635-B1 | NEUROGENESIS-STIMULATING ISOQUINOLINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2017-04-12 | — | — | EP | disclosed |
| US-9586903-B2 | Isoquinoline derivatives | HOFFMANN-LA ROCHE INC. (US) | 2017-03-07 | — | — | US | disclosed |
| US-9586903-B2 | Isoquinoline derivatives | HOFFMANN-LA ROCHE INC. (US) | 2017-03-07 | — | — | US | disclosed |
| US-9586903-B2 | Isoquinoline derivatives | HOFFMANN-LA ROCHE INC. (US) | 2017-03-07 | — | — | US | disclosed |
| EP-2991635-A1 | NEUROGENESIS-STIMULATING ISOQUINOLINE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2016-03-09 | — | — | EP | disclosed |
| US-20160046583-A1 | ISOQUINOLINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2016-02-18 | — | — | US | disclosed |
| US-20160046583-A1 | ISOQUINOLINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2016-02-18 | — | — | US | disclosed |
| US-20160046583-A1 | ISOQUINOLINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2016-02-18 | — | — | US | disclosed |
| WO-2014177596-A1 | NEUROGENESIS-STIMULATING ISOQUINOLINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2014-11-06 | — | — | WO | disclosed |
| WO-2014177596-A1 | NEUROGENESIS-STIMULATING ISOQUINOLINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2014-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160046583-A1 | ISOQUINOLINE DERIVATIVES | CDR2, DRD2, HCRTR1 | MAPK14 2643/4885CCNC 945/4885CDK8 3480/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.